Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History FBIO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics FBIO

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Fortress Biotech Inc

FBIO
Current price
1.97 USD +0.03 USD (+1.55%)
Last closed 1.94 USD
ISIN US34960Q3074
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 58 844 100 USD
Yield for 12 month -2.48 %
1Y
3Y
5Y
10Y
15Y
FBIO
21.11.2021 - 28.11.2021

Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-nodular moderate to severe acne vulgaris; Zilxi for inflammatory lesions of rosacea; Exelderm, an antifungal cream and solution for topical use; Targadox, an oral doxycycline drug for therapy for severe acne; and Luxamend, a water-based emulsion to provide a moist healing environment for superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, sunburns, and radiation dermatitis. It also develops intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for Menkes disease; UNLOXCYT for metastatic cutaneous squamous cell carcinoma; Olafertinib for EGFR mutation-positive NSCLC; CAEL-101, a monoclonal antibody for amyloid light chain amyloidosis; and Triplex, a cytomegalovirus vaccine. In addition, the company's early-stage product candidates include Dotinurad for gout; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma and anaplastic astrocytoma; MB-106 for B-cell non-hodgkin lymphoma; AJ201, an androgen receptor degradation enhancer; and BAER-101, a positive allosteric modulator. Further, its preclinical product candidates comprise AAV-ATP7A and AVTS-001 gene therapies; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida. Address: 1111 Kane Concourse, Bay Harbor Islands, FL, United States, 33154

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

10.00 USD

P/E Ratio

Dividend Yield

Financials FBIO

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures FBIO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+57 675 000 USD

Last Year

+84 513 000 USD

Current Quarter

+13 139 000 USD

Last Quarter

+15 120 000 USD

Current Year

+36 796 000 USD

Last Year

+61 620 000 USD

Current Quarter

+8 349 000 USD

Last Quarter

+12 883 000 USD
EBITDA -84 282 000 USD
Operating Margin TTM -169.85 %
Price to Earnings
Return On Assets TTM -32.37 %
PEG Ratio -0.10
Return On Equity TTM -746.25 %
Wall Street Target Price 10.00 USD
Revenue TTM 57 784 000 USD
Book Value 0.75 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 0.80 %
Dividend Yield
Gross Profit TTM 2 137 000 USD
Earnings per share -2.13 USD
Diluted Eps TTM -2.13 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin -71.24 %

Stock Valuation FBIO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 0.72
Price Sales TTM 1.02
Enterprise Value EBITDA -0.29
Price Book MRQ 2.65

Technical Indicators FBIO

For 52 Weeks

1.33 USD 2.89 USD
50 Day MA 1.83 USD
Shares Short Prior Month 3 294 028
200 Day MA 1.76 USD
Short Ratio 14.26
Shares Short 3 196 641
Short Percent 14.12 %